Eligo Bioscience

OmicEra Diagnostics

Ochre Bio

Ochre Bio Logo

Turbine AI

The London-based company has a cell simulation platform that is able to predict the effectiveness of cancer treatments.
John Doe
Founder & CEO

Phagomed

Gold Track-supported start-up, PhagoMed has been acquired by BioNTech SE, a Nasdaq traded company for approximately €130 million.
John Doe
Founder & CEO